Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Women's Mental Health

01-12-2011 | Original Article

Effect of estrogen replacement therapy on symptoms of depression and anxiety in non-depressive menopausal women

A randomized double-blind, controlled study

Published in: Archives of Women's Mental Health | Issue 6/2011

Login to get access

Abstract

The efficacy of estrogen replacement therapy (ERT) for mood disturbances associated with menopause has yet to be firmly established. The objective of this study was to investigate the efficacy of ERT for improving mood and anxiety of non-depressive postmenopausal women. This double-blind, randomized, placebo-controlled study involved two treatment groups: one receiving conjugated equine estrogens (CEEs; 0.625 mg/day) and the other placebo, for six cycles of 28 days each. Subjects were hysterectomized, healthy, non-depressive (according to Schedule for Affective Disorders and Schizophrenia, Life Time Version [SADS-L]) women. Depressive and anxiety symptoms were assessed with the Beck Depression Inventory (BDI), and the Hamilton Anxiety Scale (HAMA), respectively. The Profile of Mood States (POMS) and other scales were used to characterize symptoms. In both groups, BDI scores were significantly lower at cycles 1, 2, 3, and 6, compared with baseline assessments (p < 0.01). Anxiety scores for both groups significantly improved from cycle 3 to study endpoint. The only significant difference favoring the active group occurred at cycle 1. POMS scores were significantly improved at the end of cycles 1, 2, 3 and 6 among treated subjects and at the end of cycles 2, 3, and 6 among placebo subjects. ERT is not associated with improvements in mood or anxiety symptoms in non-depressive, hysterectomized, postmenopausal women.
Literature
Amin Z, Canli T, Epperson CN (2005) Effect of estrogen–serotonin interactions on mood and cognition. Behav Cogn Neurosci Rev 4(1):43–58PubMedCrossRef
Barrett-Connor E (1998) Hormone replacement therapy. Br Med J 317(7156):457–461CrossRef
Biagio AMB, Natalicio L (1979) Manual para o inventário de ansiedade traço-estado (IDATE). Centro Editor de Psicologia Aplicada, Rio de Janeiro
Bloch M, Schmidt PJ, Danaceau M, Murphy J, Nieman L, Rubinow DR (2000) Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 157(6):924–930PubMedCrossRef
Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F (2009) Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS One 4(3):e4824PubMedCrossRef
Bungay GT, Vessey MP, McPherson CK (1980) Study of symptoms in middle life with special reference to the menopause. Br Med J 281(6234):181–183PubMedCrossRef
Campbell S, Whitehead M (1977) Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 4(1):31–47PubMed
Colagiuri B, Morley K, Boakes R, Haber P (2009) Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence. Psychother Psychosom 78(3):167–171PubMedCrossRef
Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ et al (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332(24):1589–1593PubMedCrossRef
Daniel JM, Sulzer JK, Hulst JL (2006) Estrogen increases the sensitivity of ovariectomized rats to the disruptive effects produced by antagonism of D2 but not D1 dopamine receptors during performance of a response learning task. Horm Behav 49(1):38–44PubMedCrossRef
Deecher D, Andree TH, Sloan D, Schechter LE (2008) From menarche to menopause: exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology 33(1):3–17PubMedCrossRef
DeSoto MC (2003) Drops in estrogen levels affect brain, body and behavior: reported relationship between attitudes and menopausal symptoms. Maturitas 45(4):299–301PubMedCrossRef
Ditkoff EC, Crary WG, Cristo M, Lobo RA (1991) Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 78(6):991–995PubMed
Enck P, Benedetti F, Schedlowski M (2008) New insights into the placebo and nocebo responses. Neuron 59(2):195–206PubMedCrossRef
Farquhar D (2002) Postmenopausal hormone replacement therapy for chronic disease prevention: results from the Women's Health Initiative trial. Can Med Assoc J 167(4):377–378
Fedor-Freybergh P (1977) The influence of oestrogens on the wellbeing and mental performance in climacteric and postmenopausal women. Acta Obstet Gynecol Scand Suppl 64:1–91PubMed
Freeman EW, Sammel MD, Lin H (2009) Temporal associations of hot flashes and depression in the transition to menopause. Menopause 16(4):728–734PubMedCrossRef
Frye CA (2009) Steroids, reproductive endocrine function, and affect. A review. Minerva Ginecol 61(6):541–562PubMed
Gath D, Iles S (1990) Depression and the menopause. Br Med J 300(6735):1287–1288CrossRef
Gjerris A, Bech P, Bojholm S, Bolwig TG, Kramp P, Clemmesen L et al (1983) The Hamilton Anxiety Scale. Evaluation of homogeneity and inter-observer reliability in patients with depressive disorders. J Affect Disord 5(2):163–170PubMedCrossRef
Gorenstein C, Andrade L (1996) Validation of a Portuguese version of the Beck Depression Inventory and the State–Trait Anxiety Inventory in Brazilian subjects. Braz J Med Biol Res 29(4):453–457PubMed
Graziottin A, Serafini A (2009) Depression and the menopause: why antidepressants are not enough? Menopause Int 15(2):76–81PubMedCrossRef
Halbreich U, Kahn LS (2001) Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 15(10):797–817PubMedCrossRef
Hauser GA, Huber IC, Keller PJ, Lauritzen C, Schneider HP (1994) Evaluation of climacteric symptoms (Menopause Rating Scale). Zentralbl Gynakol 116(1):16–23PubMed
Hsiao CC, Liu CY, Hsiao MC (2004) No correlation of depression and anxiety to plasma estrogen and progesterone levels in patients with premenstrual dysphoric disorder. Psychiatry Clin Neurosci 58(6):593–599PubMedCrossRef
Hunter MS (1996) Depression and the menopause. Br Med J 313(7067):1217–1218CrossRef
Huo L, Straub RE, Roca C, Schmidt PJ, Shi K, Vakkalanka R et al (2007) Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry 62(8):925–933PubMedCrossRef
Joffe H, Cohen LS (1998) Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Biol Psychiatry 44(9):798–811PubMedCrossRef
Judd FK, Hickey M, Bryant C (2011) Depression and midlife: are we overpathologising the menopause? J Affect Disord. Jan 24 [Epub ahead of print].
Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ (1999) Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 130(7):545–553PubMed
Klaiber EL, Broverman DM, Vogel W, Kobayashi Y (1979) Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry 36(5):550–554PubMedCrossRef
Klaiber EL, Broverman DM, Vogel W, Peterson LG, Snyder MB (1996) Individual differences in changes in mood and platelet monoamine oxidase (MAO) activity during hormonal replacement therapy in menopausal women. Psychoneuroendocrinology 21(7):575–592PubMedCrossRef
Kothari S, Thacker H (1999) Risk assessment of the menopausal patient. Med Clin North Am 83(6):1489–1502PubMedCrossRef
Kupperman HS, Blatt MH, Wiesbader H, Filler W (1953) Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 13(6):688–703PubMedCrossRef
Magos AL, Brewster E, Singh R, O'Dowd T, Brincat M, Studd JW (1986) The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol 93(12):1290–1296PubMedCrossRef
Maki PM, Freeman EW, Greendale GA, Henderson VW, Newhouse PA, Schmidt PJ, Scott NF, Shively CA, Soares CN (2010) Summary of the National Institute on Aging-sponsored conference on depressive symptoms and cognitive complaints in the menopausal transition. Menopause 14(4):815–822CrossRef
McKinlay JB, McKinlay SM, Brambilla D (1987) The relative contributions of endocrine changes and social circumstances to depression in mid-aged women. J Health Soc Behav 28(4):345–363PubMedCrossRef
Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG et al (1998) Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. Br Med J 316(7148):1858–1863CrossRef
Montgomery JC, Appleby L, Brincat M, Versi E, Tapp A, Fenwick PB et al (1987) Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet 1(8528):297–299PubMedCrossRef
Morrison MF, Kallan MJ, Ten Have T, Katz I, Tweedy K, Battistini M (2004) Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry 55(4):406–412PubMedCrossRef
Norris H (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 10(21):181–191PubMedCrossRef
Pearce J, Hawton K, Blake F, Barlow D, Rees M, Fagg J et al (1997) Psychological effects of continuation versus discontinuation of hormone replacement therapy by estrogen implants: a placebo-controlled study. J Psychosom Res 42(2):177–186PubMedCrossRef
Pollo A, Benedetti F (2009) The placebo response: neurobiological and clinical issues of neurological relevance. Prog Brain Res 175:283–294PubMedCrossRef
Pollock V, Cho DW, Reker D, Volavka J (1979) Profile of Mood States: the factors and their physiological correlates. J Nerv Ment Dis 167(10):612–614PubMedCrossRef
Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Wager SG, Nunes E et al (1989) Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 46(9):787–793PubMedCrossRef
Scali J, Ryan J, Carrière I, Dartigues J-F, Tavernier B, Ritchie K, Ancelin M-L (2010) The effect of HRT some years after menopause and in older women appears to improve depressive symptoms and prevent the occurrence of depression. J Clin Psychiatry 71(12):1673–1679PubMedCrossRef
Schmidt PJ, Rubinow DR (1991) Menopause-related affective disorders: a justification for further study. Am J Psychiatry 148(7):844–852PubMed
Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR (1998) Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 338(4):209–216PubMedCrossRef
Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, Rubinow DR (2000) Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 183(2):414–420PubMedCrossRef
Sherwin BB (1991) The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 72(2):336–343PubMedCrossRef
Shetty KD, Vogt WB, Bhattacharya J (2009) Hormone replacement therapy and cardiovascular health in the United States. Med Care 47(5):600–606PubMedCrossRef
Siddle NC, Fraser D, Whitehead MI, Jesinger DK, Endacott J, Prescott P et al (1990) Endometrial, physical and psychological effects of postmenopausal oestrogen therapy with added dydrogesterone. Br J Obstet Gynaecol 97(12):1101–1107PubMedCrossRef
Soares CN (2010b) Is there a role for estrogen in treating depression during menopause? J Psychiatry Neurosci 35(6):E6–E7PubMedCrossRef
Soares CN, Maki PM (2010) Menopausal transition, mood, and cognition: an integrated view to close the gaps. Menopause 17(4):814–814
Soares CN, Almeida OP, Joffe H, Cohen LS (2001) Efficacy of estradiol for the treatment of fepressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 58(6):529–534PubMedCrossRef
Sougey EB (1987) As escalas de avaliação nos ensaios clínics com benzodiazepínicos. A proposta da escala de ansiedade de Hamilton. J Bras Psiq 36:49–53
Spitzer RL, Endicott J (1978) Schedule for Affective Disorders and Schizophrenia, Life-Time version – SADS-L NIMH. Clinical Research Collaborative Branch Program on the Psychobiology of Depression, 3 rd ed, May/78–September/79 [Portuguese translation by Gentil Filho, V.], 46 pp
Stahl SM (1997) Estrogen makes the brain a sex organ. J Clin Psychiatry 97; 58(10):421–422
Studd J (1992) Oestrogens and depression in women. Br J Hosp Med 48(5):211–213PubMed
Wilson RA, Brevetti RE, Wilson TA (1963) Specific procedures for the elimination of the menopause. West J Surg Obstet Gynecol 71(1):110–121
Metadata
Title
Effect of estrogen replacement therapy on symptoms of depression and anxiety in non-depressive menopausal women
A randomized double-blind, controlled study
Publication date
01-12-2011
Published in
Archives of Women's Mental Health / Issue 6/2011
Print ISSN: 1434-1816
Electronic ISSN: 1435-1102
DOI
https://doi.org/10.1007/s00737-011-0241-3